Literature DB >> 20547927

Formation of plexiform lesions in experimental severe pulmonary arterial hypertension.

Kohtaro Abe1, Michie Toba, Abdallah Alzoubi, Masako Ito, Karen A Fagan, Carlyne D Cool, Norbert F Voelkel, Ivan F McMurtry, Masahiko Oka.   

Abstract

BACKGROUND: The plexiform lesion is the hallmark of severe pulmonary arterial hypertension. However, its genesis and hemodynamic effects are largely unknown because of the limited availability of lung tissue samples from patients with pulmonary arterial hypertension and the lack of appropriate animal models. This study investigated whether rats with severe progressive pulmonary hypertension developed plexiform lesions. METHODS AND
RESULTS: After a single subcutaneous injection of the vascular endothelial growth factor receptor blocker Sugen 5416, rats were exposed to hypoxia for 3 weeks. They were then returned to normoxia for an additional 10 to 11 weeks. Hemodynamic and histological examinations were performed at 13 to 14 weeks after the Sugen 5416 injection. All rats developed pulmonary hypertension (right ventricular systolic pressure approximately 100 mm Hg) and severe pulmonary arteriopathy, including concentric neointimal and complex plexiform-like lesions. There were 2 patterns of complex lesion formation: a lesion forming within the vessel lumen (stalk-like) and another that projected outside the vessel (aneurysm-like). Immunohistochemical analyses showed that these structures had cellular and molecular features closely resembling human plexiform lesions.
CONCLUSIONS: Severe, sustained pulmonary hypertension in a very late stage of the Sugen 5416/hypoxia/normoxia-exposed rat is accompanied by the formation of lesions that are indistinguishable from the pulmonary arteriopathy of human pulmonary arterial hypertension. This unique model provides a new and rigorous approach for investigating the genesis, hemodynamic effects, and reversibility of plexiform and other occlusive lesions in pulmonary arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547927     DOI: 10.1161/CIRCULATIONAHA.109.927681

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  220 in total

1.  Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans.

Authors:  Harm J Bogaard; Shiro Mizuno; Christophe Guignabert; Aysar A Al Hussaini; Daniela Farkas; Gerrina Ruiter; Donatas Kraskauskas; Elie Fadel; Jeremy C Allegood; Marc Humbert; Anton Vonk Noordegraaf; Sarah Spiegel; Laszlo Farkas; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

2.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

3.  [Histopathological aspects of pulmonary hypertension].

Authors:  D Jonigk; M M Hoeper; H Kreipe; F Länger
Journal:  Pathologe       Date:  2012-05       Impact factor: 1.011

Review 4.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

5.  Nestin-expressing vascular wall cells drive development of pulmonary hypertension.

Authors:  Farhan Saboor; Ansgar N Reckmann; Claudia U M Tomczyk; Dorothea M Peters; Norbert Weissmann; Andre Kaschtanow; Ralph T Schermuly; Tatyana V Michurina; Grigori Enikolopov; Dieter Müller; Andrea Mietens; Ralf Middendorff
Journal:  Eur Respir J       Date:  2015-12-23       Impact factor: 16.671

6.  Association between endothelial function and micro-vascular remodeling measured by synchrotron radiation pulmonary micro-angiography in pulmonary arterial hypertension.

Authors:  Satoko Fuji; Shonosuke Matsushita; Kazuyuki Hyodo; Motoo Osaka; Hiroaki Sakamoto; Kenkichi Tanioka; Kazunori Miyakawa; Misao Kubota; Yuji Hiramatsu; Chiho Tokunaga
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-07-08

7.  Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.

Authors:  Helen Christou; Hannes Hudalla; Zoe Michael; Evgenia J Filatava; Jun Li; Minglin Zhu; Jose S Possomato-Vieira; Carlos Dias-Junior; Stella Kourembanas; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2017-12-06       Impact factor: 4.030

8.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

9.  Carfilzomib reverses pulmonary arterial hypertension.

Authors:  Xinhong Wang; Yasmine F Ibrahim; Dividutta Das; Makhosazane Zungu-Edmondson; Nataliia V Shults; Yuichiro J Suzuki
Journal:  Cardiovasc Res       Date:  2016-03-06       Impact factor: 10.787

10.  Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.

Authors:  Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.